Clinical Trial

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Study acronym: MARITIME-CV
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Protocol Amendment History 5 changes
notable Trial sites expanded: 774 -> 781 locations 2026-07-11
notable Trial sites expanded: 769 -> 772 locations 2026-05-30
notable Trial sites expanded: 766 -> 769 locations 2026-05-23
notable Trial sites expanded: 759 -> 765 locations 2026-05-12
notable Trial sites expanded: 726 -> 758 locations 2026-04-21
Trial Details
NCT Number NCT07037433
Lead Sponsor Amgen
Conditions Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Enrollment 12,800 participants
Start Date 2025-07-25
Primary Completion 2028-06-30 (estimated)
Study Completion 2030-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-10